August 09 2020

NIMODIPINE

List of brands containing nimodipine   

This page contains list of brands of authorized pharmaceutical specialties of the active principle nimodipine in the countries listed below:

Australia] [ Brazil] [ Canada] [ France] [ Germany] [ India] [ Italy] [ Japan] [ Mexico] [ Pakistan] [ Puerto Rico] [ Spain] [ Turkey] [ United Kingdom] [ U.S.A]

Given the nature of the pharmaceutical market, some specialties may be unavailable, have been removed from the pharmaceutical market or have changed its name. So that, in no case can take decisions based on the information contained in the page. MEDIZZINE is not responsible for any damage arising from the information provided, which may be incomplete or outdated.

Indications and usage     

The active substance nimodipine belongs to a group of drugs known as antagonists of calcium channels, also called calcium channel blockers.

This drug is indicated for the prevention of deterioration of brain function after suffering an episode of subarachnoid hemorrhage (bleeding around the brain).

Nimodipine has peripheral vasodilating effects, ie, dilates the arteries and improves the oxygen supply to the brain, increasing its blood flow, counteracting the spasm of cerebral arteries, which prevents damage from lack of oxygen in tissues brain.

Some Official Agencies support other indications such as the treatment of cerebral organic disorders in elderly patients with severe symptoms of memory deterioration, behavioral disorders, attention impairment and mood swings.

Medizzine recommends consulting your doctor if you are unsure (or you do not know) why you have been given nimodipine.

Other ingredients of available commercial presentations:

Tablets:

Besides the active substance, the tablets may contain microcrystalline cellulose, corn starch, povidone, crospovidone, magnesium stearate, hypromellose, macrogol 4000, titanium dioxide and yellow iron oxide.

Extended-release tablets (retard):

These pharmaceutical products may include the following excipients: Hypromellose, lactose monohydrate, colloidal silicon dioxide, magnesium stearate, sunset yellow dye (No. 10) and white opadry.

Oral solution:

Besides the active substance (2-4%), the oral solution may include castor oil, glycerin, polyethylene glycols, methylparaben, sodium phosphate monobasic, ethanol (48.06 g/100 ml) and water.

Solution for infusion:

These pharmaceutical products contain 10 mg nimodipine in 50 ml solution, including ethyl alcohol 96% (10 g), polyethylene glycol 400, sodium citrate dihydrate, citric acid anhydrous and water for injection.

Capsules:

Besides the active principle, these presentations may include glycerin, peppermint oil, isopropyl alcohol, butyl alcohol, polyethylene glycols, gelatin, ammonia, yellow sunset dye (No. 10), titanium dioxide, ferrous-ferric oxide, shellac, ethyl alcohol, propylene glycol, medium chain triglycerides and water.

Warning:

The composition of the various presentations may vary from one country to another. We recommend you consult the information provided by your local supplier.

Important information     

Extended-release tablets:

This medicine may contain lactose. If your doctor has told you that you have an intolerance to certain sugars, consult him before taking it.

This medicine may contain yellow sunset dye (E110) which may cause allergic reactions, including asthma, especially in patients with allergy to acetylsalicylic acid (aspirin®).

Oral solution:

This medicine may contain methylparaben, which may cause allergic reactions, possibly delayed.

This medicine may contain up to 408 mg/ml ethyl alcohol, equivalent to 8.16 grams alcohol for each 60 mg nimodipine 0.3% (60 mg/20 ml), equivalent to 113 ml of beer which may be harmful to patients with addiction to alcohol, pregnant or are breastfeeding, children and high-risk patients for developing major diseases of the liver (cirrhosis, liver failure) or epilepsy.

This medicine may contain castor oil, which can lead to stomach upset and diarrhea.

Injectable solution:

This medicine contains 10 grams ethyl alcohol per dose (50 ml), which is equivalent to 238 ml beer (or 99 ml common wine) in each dose. This may be harmful to patients with addiction to alcohol, pregnant or breastfeeding women, children and high-risk patients for developing major diseases of the liver (cirrhosis, liver failure) or epilepsy.

The ethanol amount supplied by a 50 ml solution container can alter the effects of other drugs that the patient could take simultaneously such as medicines acting on the nervous system (sedatives, antipsychotics, etc.).

Capsules:

This medicine may contain yellow sunset dye, which can cause allergic reactions, including asthma, especially in patients who are allergic to acetylsalicylic acid (aspirin®).

Before taking the drug     

Do not use nimodipine

If you are allergic (hypersensitive) to nimodipine or any of the other ingredients of the medicinal product prescribed to you. If you think may be allergic, ask your doctor.

Allergy symptoms may include:

- Asthma attacks with shortness of breath, audible wheezing or rapid breathing.
- More or less sudden swelling of the face, lips, tongue or elsewhere in the body. It is especially critical if it affects the vocal cords.
- Hives, itching, rash
- Anaphylactic shock (loss of consciousness, paleness, sweating, etc.).

Nor you should take this medicine:

- At the same time both oral as injectable,
- If you have recently had a heart attack,
- If you have angina and observe an increase in the frequency and severity of attacks,
- If you are taking rifampicin, an antibiotic drug,
- If you are taking phenobarbital, phenytoin or carbamazepine (medicines to treat epilepsy).

Take special care with nimodipine

Consult your doctor before you start taking this medicine:

- If you have low blood pressure or are being treated to lower blood pressure.
- If you have any liver or kidney disorder,
- If you suffer from cerebral edema (fluid accumulation in an area or all the brain) or have increased pressure inside the skull (intracranial hypertension),
- If you have suffered a head injury that may have caused an internal hemorrhage (subarachnoid hemorrhage),
- If you have unstable angina or less than a month ago that has suffered an acute myocardial infarction,
- If you have heart problems such as heart arrhythmias and heart failure; in these cases, your doctor will perform regular checks.

Remember that your doctor has prescribed this medicine only for you. Never give it to someone else.

If in doubt, consult your doctor.

Taking other medicines

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including herbal products or drugs obtained without a prescription.

Nimodipine should not be given together with rifampicin, phenobarbital, phenytoin or carbamazepine since these drugs are enzyme inducers that favor the elimination of nimodipine.

Some medicines may influence the action of nimodipine:

- Antihypertensive medicines, such as nifedipine, diltiazem, verapamil, alpha-methyldopa, alpha-blockers or beta-blockers.

Nimodipine may increase the effect of these drugs:

- Cimetidine, an antiulcer drug,
- Sodium valproate, a drug to treat epilepsy.

The following medicines may increase the effect of nimodipine:

- Antidepressants, such as fluoxetine and nefazodone,
- Zidovudine, indinavir, ritonavir, nelfinavir o saquinavir (medicines for the treatment of HIV infection),
- Erythromycin,
- Ketoconazole, itraconazole or fluconazole.
- The association quinupristin/dalfopristin.

Use with food and beverages

This medicine can be taken before, after or with meals. However, it seems advisable to take the oral forms one hour before or two hours after a meal, as food can reduce the absorption of the drug.

You should not consume grapefruit or grapefruit juice while being treated with this drug. You should leave a gap of four days between the consumption of grapefruit (or juice) and the start of treatment with nimodipine. This fruit can raise levels of nimodipine over a period of four days after ingestion. Tell your doctor if you have recently eaten grapefruit

Consult your doctor or pharmacist before taking any medicine.

Special physiological situations

Pregnancy and lactation:

Always consult your doctor or pharmacist before taking any medicine during pregnancy or breastfeeding.

If you are pregnant, planning to become pregnant or think you are pregnant, tell your doctor before taking this medicine and follow their advice carefully.

Do not breastfeed your child while you are treated with nimodipine.

Warning to potential fathers:

Nimodipine may impair male fertility. This must be considered if you and your wife are trying to have children.

Use in children

It is not established the efficacy and safety of use of nimodipine in children, so it is not recommended in this age group.

Use in elderly

Nimodipine should be administered with great caution to elderly patients since at this age, there is a higher incidence of decreased visceral functions (hepatic, renal and cardiac), in addition to being very frequent the simultaneous use of other drugs.

Driving and using machines

This medicine may make you feel dizzy. If so, you should avoid handling potentially dangerous machinery or drive vehicles.

The amount of alcohol in this medicine in the injection solution can decrease the ability to drive or operate machinery.

Consult your doctor or pharmacist before taking any medicine.

How to use nimodipine     

Follow carefully instructions of use of nimodipine provided by your doctor. Consult your doctor or pharmacist when in doubt. Follow the instructions of the physician in preference to those given in this website, which may be different. Ask your doctor to explain any aspect that you do not understand, contained in the instruction leaflet that comes with the medicine.

The solution for infusion is a medicine for hospital use so that the dose and duration will be determined by the physician in charge of patient care, according to the circumstances of each case.

Commonly, the drug is administered over a period of one to two weeks in IV infusion, followed by 360 mg/day orally, divided into six doses of 60 mg (two tablets, capsules, or single-dose oral solution) to complete a full cycle of three weeks.

Patients with liver or kidney failure will be assessed individually in order to adjust the dose to the circumstances of each one.

If you think the effect of the medicine is too strong or too weak, consult your doctor.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

While you take nimodipine     

If a doctor prescribes another medicine, tell you are taking nimodipine.

Check with your doctor regularly developments of disorder that motivates the use of nimodipine. Maybe there is some reason that prevented you properly receive the indicated doses and induce your doctor to erroneous conclusions about treatment.

Do not restart treatment with nimodipine at your own risk without first talking to your doctor, nor encourage its use by another person, even if have the same symptoms you have. Nor is it advisable to interrupt or reduce the dose without considering the opinion of your doctor.

If you feel unwell during treatment with nimodipine, immediately consult your doctor.

If you take more than you should:

Consult your doctor or pharmacist immediately or call the National Toxicological Information Service in your country. If you have taken an overdose of telmisartan, go to the emergency department of the nearest hospital. Take the container with you, even if it is empty.

Excessive doses can cause a severe drop in blood pressure, heart rhythm disturbances (tachycardia, bradycardia), nausea, digestive disorders and feeling weak or sick.

If you forget to take nimodipine

If you forget to take your medicine, take the dose as soon as you remember, continuing taking the doses every four hours. Do not take a double dose to make up for missed doses.

If you stop taking nimodipine

Do not stop treatment without consulting your doctor.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Side Effects of nimodipine     

Like all medicines, nimodipine can cause side effects although not everybody gets them.

The frequency of side effects is classified into:

Very common: affect 1 out of 1-10 patients
Common: affect 1 out of 10-100 patients
Uncommon: affect 1 out of 100-1.000 patients
Rare: affect 1 out of 1.000-10.000 patients
Very Rare: affect less than 1 in 10,000 patients
Incidence not known: Can not be established the true incidence from the available data

Potentially serious side effects:

If you experience:

- Allergic reaction,
- Reduction of low blood pressure (can cause dizziness and weakness),
- Bradycardia (slow heartbeat),
- Easy bruising and bleeding caused by reduced platelet count (thrombocytopenia).

Consult your doctor immediately if you notice any of the above side effects

Other less serious side effects:

Uncommon side effects:

- Rash,
- Headache,
- Fast heartbeats,
- Hot flashes, sweating, feeling hot,
- Feeling of discomfort, nausea,

Rare side effects:

- Constipation.
- A slight increase in liver enzymes (transaminases, alkaline phosphatase, etc.).

This list does not include all adverse reactions associated with the use of nimodipine, both well established as those that are under consideration or confirmation. In case you feel unwell, should immediately consult with the doctor who prescribed this medicine.

If you notice any side effects not listed in this website or in the leaflet accompanying the package, ask your doctor or pharmacist.

If any of the side effects gets serious, tell your doctor or pharmacist.

List of brands containing nimodipine     

This page contains list of brands of authorized pharmaceutical specialties of the active principle nimodipine in the countries listed below:

Australia] [ Brazil] [ Canada] [ France] [ Germany] [ India] [ Italy] [ Japan] [ Mexico] [ Pakistan] [ Puerto Rico] [ Spain] [ Turkey] [ United Kingdom] [ U.S.A]

Given the nature of the pharmaceutical market, some specialties may be unavailable, have been removed from the pharmaceutical market or have changed its name. So that, in no case can take decisions based on the information contained in the page. MEDIZZINE is not responsible for any damage arising from the information provided, which may be incomplete or outdated.

Warning:

With exceptions expressly indicated, these lists do not include active principle associations with other drugs or clinical use containers.

Australia:     

NIMOTOP 30 mg, 100 tablets
NIMOTOP 10 mg/50 ml, solution for infusion

Brazil:     

NIMODIPINO GERMED 30 mg, 30 tablets
NIMODIPINO EMS 30 mg, 30 tablets
NIMODIPINO LEGRAND 30 mg, 30 tablets
NIMODIPINO SANDOZ 30 mg, 30 tablets
NIMOPAX 30 mg, 30 tablets
NIMOTOP 30 mg, 30 tablets
NIMOVAS 30 mg, 30 tablets
OXIGEN 10 mg/50 ml, solution for infusion
OXIGEN 30 mg, 30 and 60 tablets
OXIGEN 40 mg/ml, 25 ml oral drops

Canada:     

NIMOTOP 30 mg, 100 tabletas

France:     

NIMOTOP 30 mg, 90 tablets
NIMOTOP 10 mg/50 ml, solution for infusion

Germany:     

NIMODIPIB HEXAL 30 mg, 30, 60 and 120 tabletas
NIMODIPIN CARINO 10 mg/50 ml, solution for infusion
NIMOTOP 30 mg, 30 and 100 tabletas
NIMOTOP S 10 mg/50 ml, solution for infusion
NIMOTOP S 30 mg, 30 and 100 tabletas

India:     

MD-NEURO 30 mg, tablets
MODIPIN 30 mg, capsules
MODIPIN 10 mg/50 mL solution for infusion
NIMOCARD 10 mg/50 mL solution for infusion
NIMOCER 30 mg, tablets
NIMODEC 10 mg/50 mL solution for infusion
NIMODEC 30 mg, tablets
NIMODIP 30 mg, tablets
NIMODIP 10 mg/50 mL solution for infusion
NIMOTIDE 30 mg, tablets
VASOTOP 30 mg, tablets
VASOTOP 10 mg/50 mL solution for infusion

Italy:     

ISKIDROP 30 mg/0.75 ml, 25 ml oral drops
KAPPAFLUX 30 mg/0.75 ml, 25 ml oral drops
NIMOBRAIN 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA DOC GENERICI 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA EG 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA GERMED 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA HEXAL 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA MYLAN GENERICS 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA PENSA 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA RATIOPHARM 30 mg/0.75 ml, 25 ml oral drops
NIMODIPINA SANDOZ 30 mg/0.75 ml, 25 ml oral drops
NIMOTOP 10 mg/50 ml, solution for infusion
NIMOTOP 30 mg, 36 tablets
NIMOTOP 30 mg, 36 sachets effervescent granules
NIMOTOP 30 mg/0.75 ml, 25 ml oral drops
PERIBRAIN 30 mg/0.75 ml, 25 ml oral drops
PERIBRAIN 30 mg/0.75 ml, 30 single-dose 0.75 ml oral drops
PERIPLUM 30 mg, 36 tablets
PERIPLUM 30 mg/0.75 ml, 25 ml oral drops
PERIPLUM 10 mg/50 ml, solution for infusion
VAXOCIN 30 mg/0.75 ml, 30 single-dose 0.75 ml oral drops
VAXOCIN 30 mg/0.75 ml, 25 ml oral drops

Japan:     

N/A

Mexico:     

KENZOLOL 10 mg/50 ml, solution for infusion
KENZOLOL T 30 mg, 30, 60 and 90 tabletas
NIMOTOP 10 mg/50 ml, solution for infusion
NIMOTOP 30 mg, 30, 60 and 90 tabletas
VACER 30 mg, 10, 20 and 30 tabletas

Pakistan:     

BREDIN 30 mg, tablets
BREDIN 0.2 mg/ml, solution for infusion
DURANIM 30 mg, tablets
NIDOPIN 30 mg, tablets
NIMODEN 30 mg, tablets
NIMODEX 30 mg, tablets
NIMOPRO 30 mg, tablets
NIMOTIN 30 mg, tablets
NIMOTOP 30 mg, tablets
NIMOTOP 0.2 mg/ml, solution for infusion
NIMOVAS 30 mg, tablets

Spain:     

BRAINAL 30 mg, 30 and 100 tablets
MODUS 30 mg, 30 and 100 tablets
NIMODIPINO G.E.S. 0,2 mg/ml, solution for infusion
NIMODIPINO REMONTAL 30 mg, 30 and 100 tablets
NIMODIPINO STADA 30 mg, 30 and 100 tablets
NIMOTOP 30 mg, 30 and 100 tablets
NIMOTOP 0,2 mg/ml 0,2 mg/ml, solution for infusion

Turkey:     

NIMOTOP 30 mg, 30 tablets

United Kingdom:     

NIMOTOP 0.02%, solution for infusion
NIMOTOP 30 mg, 100 tablets

U.S.A. and Puerto Rico:     

NIMODIPINE CARACO PHARMA 30 mg, 50 and 100 capsules
NIMODIPINE ASCEND 30 mg, 50 and 100 capsules
NIMODIPINE HERITAGE 30 mg, 30 and 100 capsules
NYMALIZE ARBOR PHARMA 3 mg/ml, 473 ml oral solution
NYMALIZE ARBOR PHARMA 3 mg/ml, 12 single-dose 20 ml oral solution
NIMODIPINE CARDINAL HEALTH 30 mg, 30 and 100 capsules
NIMODIPINE GOLDEN STATE MED SUPP 30 mg, 30 and 100 capsules

Page updated: December 11, 2010.